 |
Case Report
Asymptomatic cytomegalovirus reactivation associated with Alemtuzumab in multiple sclerosis: A treatment dilemma
1 Infectious Diseases and Tropical Medicine Department, Hospital de Egas Moniz – Centro Hospitalar de Lisboa Ocidental, Rua da Junqueira 126, Lisbon, Portugal
2 Neurology Department, Hospital de Egas Moniz – Centro Hospitalar de Lisboa Ocidental, NOVA Medical School – Universidade Nova de Lisboa, Rua da Junqueira 126, Lisbon, Portugal
Address correspondence to:
Joana Granado
Rua da Junqueira 126, 1349-019 Lisbon,
Portugal
Message to Corresponding Author
Article ID: 100010Z16JG2021
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Granado J, Correia AS, Casanova S, Miranda AC, Mansinho K. Asymptomatic cytomegalovirus reactivation associated with Alemtuzumab in multiple sclerosis: A treatment dilemma. J Case Rep Images Infect Dis 2021;4:100010Z16JG2021.ABSTRACT
Introduction: Alemtuzumab is a monoclonal antibody recently used for the treatment of relapsing-remitting multiple sclerosis (MS). It has been associated with cytomegalovirus (CMV) clinical reactivation and end-organ disease which may be severe.
Case Report: We present the case of a patient with an asymptomatic CMV reactivation after a pre-emptive approach, with no disease related sequels.
Conclusion: Although a few cases of CMV reactivation associated to Alemtuzumab in the treatment of relapsing-remitting MS have been reported, there are no guidelines on how to manage those patients in order to prevent CMV disease.
Keywords: Alemtuzumab, Cytomegalovirus reactivation, CD4+ T-cells, Multiple sclerosis
SUPPORTING INFORMATION
Acknowledgments
The authors want to thank Dr. Pedro Pires for helping in the revision and writing of this article.
Author ContributionsJoana Granado - Substantial contributions to conception and design, Acquisition of data, Analysis of data, Interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Ana Sofia Correia - Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Sara Casanova - Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Ana Cláudia Miranda - Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Kamal Mansinho - Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2021 Joana Granado et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
